
Julie Fisher
Kate's Project 2018 (part 3)

Total raised
£30,000.00
+ £162.70 Gift Aid
This Giving Page is now closed
Thank you for raising money for life-saving work. All the money raised is being used to help beat cancer
Still want to donate?
I’m fundraising to raise money for Cancer Research UK
My Story
Kate Guthrie was 16 months old when she was diagnosed with a rhabdomyosarcoma. She underwent two major surgeries, massive amounts of chemo and radiotherapy but at no stage did she lose her beautiful smile and the ability to make people laugh. Since Kate's death in 1994, her family have worked alongside CR-UK in trying to find out why sarcomas occur. Over the past 7 years her family and friends have raised half a million pounds to fund 9 research projects in Kate's memory. Dr Meriel Jenney is improving outcomes for newly diagnosed and relapsed children with rhabdomyosarcoma- a cancer that develops from the muscles attached to the bone. Although a relatively rare disease, rhabdomyosarcoma is the most common soft tissue sarcoma in children. Dr Jenney, a consultant paediatric oncologist at the Children's Hospital for Wales, is launching a study that aims to recruit around 1,800 people over 7 years from the UK and Europe. The study will analyse three treatment areas for patients whose cancer hasn't spread, and for the tumours deemed removable through surgery, patients will be allocated into one of two groups- either receiving pre-or-post operative radiotherapy. The second area of focus is the use of chemotherapy. New drug combinations will be trialled, comparing current options to new alternatives. They will also investigate the optimum duration of maintenance chemotherapy (a type of chemotherapy a person receives to avoid or slow the cancer's return after initial, effective treatment). The third area is understanding the underlying biology of the disease. Sometimes two genes fuse together to form a faulty molecule, which can drive cancer progression. The PAX-FOXO fusion gene is an example of this, where the PAX and FOXO genes have fused together, and is a signature genetic change known to drive rhabdomyosarcoma. All patient entries will be screened for the assessment of the PAX-FOXO fusion gene status. Tumour samples will be collected at diagnosis and relapsed disease for biological studies to facilitate the identification of treatment strategies and relevant molecules called "biomarkers" that could enable disease and patient monitoring. A virtual biobank will also be established that will enable the collected samples to be analysed for a better understanding of the biology of the disease by the research community across the globe. The trial is co-ordinated from the University of Birmingham and Dr Jenney is based in Cardiff. £30,000 covers the analysis of samples for the PAX-FOXO fusion gene from all patients on the trial- including a consultant review of cases- for the entire first year of the project. Collecting samples is crucial in a trial like this, where doctors must indentify the specific genetic faults in a patient's disease before deciding on which treatment will be most effective.
Loading

CAUSE
Dr Meriel Jenney
Dr Meriel Jenney is improving outcomes for newly diagnosed and relapsed children and adults with rhabdomyosarcoma – a cancer that develops from the muscles attached to bone. Although a relatively rare disease, rhabdomyosarcoma is the most common soft tissue sarcoma in children.
Latest updates
With Cancer Research UK Giving Pages more of the money raised goes towards beating cancer. Aside from the credit and debit card fees, every penny donated goes to Cancer Research UK.
All donations made to this page will automatically be transferred to Cancer Research UK.